Proximagen shores up business with £50 million placing
This article was originally published in Scrip
Executive Summary
Proximagen Neuroscience, the UK biopharmaceutical company, is to raise £50 million through the placement of nearly 36 million new ordinary shares of 1 pence each at a price of £1.40 per share.